What medication is represented by the brand name Anoro Ellipta?

Anoro Ellipta represents a combination of umeclidinium and vilanterol, which are both long-acting medications used primarily in the management of chronic obstructive pulmonary disease (COPD). Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax and open the airways by blocking acetylcholine at muscarinic receptors in the lungs. Vilanterol is a long-acting beta-agonist (LABA) that stimulates beta-2 adrenergic receptors, leading to bronchodilation.

This combination therapy works synergistically to improve lung function and relieve symptoms in patients with COPD. By offering both a LAMA and a LABA in a single inhaler, Anoro Ellipta provides a convenient option for patients needing dual bronchodilator therapy. This approach not only enhances patient compliance by reducing the number of inhalers needed but also maximizes the therapeutic effect on exacerbations and overall respiratory health.

The other choices listed are individual medications or different combinations used for varying indications and mechanisms of action.